Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.
Fresenius SE KGaA's Capital Expenditure for the
three
months ended in Jun. 2026 was CHF-221.93 Mil. Its Revenue for the
three
months ended in Jun. 2026 was CHF5,474.47 Mil.
Hence, Fresenius SE KGaA's Capex-to-Revenue for the
three
months ended in Jun. 2026 was 0.04.
Fresenius SE KGaA (XSWX:FRE) Capex-to-Revenue Explanation
Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.
Fresenius SE KGaA Capex-to-Revenue Related Terms
Fresenius SE KGaA Capex-to-Revenue Historical Data
* Premium members only.
The historical data trend for Fresenius SE KGaA's Capex-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:FRE vs HCA, THC, DVA: Capex-to-Revenue Comparison
For the Medical Care Facilities subindustry, Fresenius SE KGaA's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fresenius SE KGaA Capex-to-Revenue vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Fresenius SE KGaA's Capex-to-Revenue distribution charts can be found below:
* The bar in red indicates where Fresenius SE KGaA's Capex-to-Revenue falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fresenius SE KGaA (XSWX:FRE) has a Capex-to-Revenue of 0.04 as of Jun. 2026. Capex to Revenue ratio measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. View historical data on Fresenius SE KGaA and its competitors.
Is Fresenius SE KGaA's Capex-to-Revenue too high?
Fresenius SE KGaA's current Capex-to-Revenue is 0.04. Overall, Fresenius SE KGaA has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fresenius SE KGaA's Capex-to-Revenue compare to HCA and THC?
Fresenius SE KGaA's Capex-to-Revenue of 0.04 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Capex-to-Revenue for a Healthcare Providers & Services company?
A good Capex-to-Revenue depends on the Healthcare Providers & Services industry context. However, Capex-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Capex-to-Revenue mean?
A high Capex-to-Revenue can signal that a stock is expensive relative to its fundamentals. Capex to Revenue ratio measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. View historical data on Fresenius SE KGaA and its competitors. Fresenius SE KGaA's current Capex-to-Revenue is 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fresenius SE KGaA stock overvalued right now?
Based on GuruFocus' analysis, Fresenius SE KGaA (XSWX:FRE) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF35.87, compared to a current price of CHF42.86 — trading 19.5% above its estimated fair value. The current Capex-to-Revenue is 0.04. Fresenius SE KGaA's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Capex-to-Revenue calculated?
Capex-to-Revenue is calculated from a company's financial statements. For Fresenius SE KGaA (XSWX:FRE), the current Capex-to-Revenue is 0.04 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fresenius SE KGaA (XSWX:FRE) Overvalued in 2026?
Based on GuruFocus' analysis, Fresenius SE KGaA stock appears to be overvalued.
The current stock price of CHF42.86 is trading 19.5% above its estimated GF Value™ of CHF35.87.
GuruFocus considers Fresenius SE KGaA to be Modestly Overvalued.
Key valuation signals for XSWX:FRE:
Capex-to-Revenue: 0.04
GF Value™: CHF35.87 vs. price of CHF42.86 (19.5% above fair value)
No single metric tells the full story. See the XSWX:FRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fresenius is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain.
68GF Score
Get the complete analysis for XSWX:FRE
Capex-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:FRE has been successfully added to your 
